Patents by Inventor Stewart Chipman

Stewart Chipman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conjugates of biologically active polypeptides having an increased in vivo half-life
    Patent number: 8748577
    Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: June 10, 2014
    Assignee: Cell Therapeutics, Inc.
    Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
  • CONJUGATES OF BIOLOGICALLY ACTIVE PROTEINS HAVING A MODIFIED IN VIVO HALF-LIFE
    Publication number: 20120252717
    Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
    Type: Application
    Filed: January 31, 2012
    Publication date: October 4, 2012
    Applicant: CELL THERAPEUTICS, INC.
    Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
  • Conjugates of biologically active proteins having a modified in vivo half-life
    Patent number: 8129348
    Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: March 6, 2012
    Assignee: Cell Therapeutics, Inc.
    Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
  • CONJUGATES OF BIOLOGICALLY ACTIVE PROTEINS HAVING A MODIFIED IN VIVO HALF-LIFE
    Publication number: 20090298762
    Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
    Type: Application
    Filed: October 14, 2008
    Publication date: December 3, 2009
    Applicant: Cell Therapeutics, Inc.
    Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
  • Generic probes for the detection of phosphorylated sequences
    Publication number: 20060089414
    Abstract: Generic probes that bind to phosphorylated amino acid residues are provided as well as methods employing the probes for screening for kinase inhibitory activity, kinase activity, and phosphatase activity. Methods for distinguishing serine/threonine kinase phosphorylation from tyrosine kinase phosphorylation are also provided.
    Type: Application
    Filed: July 22, 2005
    Publication date: April 27, 2006
    Inventors: Kurt Morgenstern, James Boyce, Stewart Chipman
  • Methods of using IMXP-888 and IMXP-888 antagonists
    Publication number: 20050281824
    Abstract: The invention relates to the discovery that IMXP-888, a protein with homology to the FGF receptor family, is a proinflammatory cytokine. The invention encompasses therapeutic compositions of IMXP-888 polypeptides and antagonists, methods of use thereof, and screening methods.
    Type: Application
    Filed: July 21, 2005
    Publication date: December 22, 2005
    Applicant: Immunex Corporation
    Inventors: Stewart Chipman, Kenneth Schooley, Teresa Born, Robert DuBose
  • Use of debromohymenialdisine for treating osteoarthritis
    Patent number: 5591740
    Abstract: Disclosed is a method of treating osteoarthritis. The method comprises administering a therapeutic amount of debromohymenialdisine to an individual or animal with osteoarthritis. Debromohymenialdisine is able to slow the joint deterioration and cartilage degradation associated with the disease.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 7, 1997
    Assignees: OsteoArthritis Sciences, Incorporated, The Reagents of the University of California
    Inventors: Stewart Chipman, David J. Faulkner